Arbutus Biopharma Corporation

US$3.65As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:ABUSHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 1.49%
Div yield —
ROE 89.58%
Biotechnology
Beta (5Y) 0.81
PE TTM 4.629
TSR TTM (22.73%)
Mkt cap US$723.1M
ROIC 52.60%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$3.78
3.53%
(27.57%)
Hold 1|1|4|4|4
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.04
0.04
0.04
0.04
17.06%
24.73%
27.82%
35.20%
Revenue$M
62.72
62.66
65.91
66.01
14.29%
12.95%
12.77%
11.07%
Peers (US$723.1M)
Cap (US$)
PE
724.0M
—
733.7M
—
Capital
TTM
5Y
10Y
Leveragex
1.712
(1.193)
(0.950)
EBIT/Intx
0.131
0.581
0.585
Own earn%
(303.46)
(4.35)
(0.78)
Sh yield%
37.48
12.55
13.73
Owners
Insiders/Inst%
11.24
61.72
Short interest%
1.83
SBC / revenue%
4.01
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
12–18
$1 testx
—
Incr. ROIC%
6